EcoDrugPlus

Histone Deacetylase 11

Ensembl ID : ENSPREG00000020626
Gene Symbol: HDAC11
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 2

Ensembl ID : ENSPREG00000020961
Gene Symbol: HDAC2
4 Cross references
209 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSPREG00000016847
Gene Symbol: LOC103461731
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSPREG00000012588
Gene Symbol: HDAC4
3 Cross references
196 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSPREG00000005884
Gene Symbol: HDAC5
3 Cross references
194 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSPREG00000012414
Gene Symbol: HDAC6
3 Cross references
180 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSPREG00000001618
Gene Symbol: HDAC7
3 Cross references
189 Possible Orthologues:

Histone Deacetylase 7-Like

Ensembl ID : ENSPREG00000001881
Gene Symbol: LOC103464932
2 Cross references
195 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSPREG00000010598
Gene Symbol: HDAC8
3 Cross references
205 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 2-Like

Ensembl ID : ENSPREG00000007183
Gene Symbol: LOC103461512
2 Cross references
226 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSPREG00000005362
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSPREG00000015851
Gene Symbol: HCN4
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).